Moroctocog alfa
Sold as Refacto, Xyntha
Every registration of this product has been cancelled.
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 1
- Registrations
- 3
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pfizer Laboratories (Pty) LtdCancelled | Refacto, Xyntha | 000 I.U, 1, 250 IU, 500 I.U | 350066, 350067, 350068 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Refacto 250 IU EACH 10,0 ml VIAL CONTAINS MOROCTOCOG ALFA 250,0 iu | 250 IU | 35006635/8.1/0066 | Cancelled | Not determined | None |
| Xyntha 500 I.U. EACH 10,0 ml VIAL CONTAINS MOROCTOCOG ALFA 500,0 iu | 500 I.U. | 35006735/8.1/0067 | Cancelled | Not determined | None |
| Xyntha 1 000 I.U. EACH 10,0 ml VIAL CONTAINS MOROCTOCOG ALFA 1000,0 iu | 000 I.U. 1 | 35006835/8.1/0068 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.